WO2021100614A1 - 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 - Google Patents
大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 Download PDFInfo
- Publication number
- WO2021100614A1 WO2021100614A1 PCT/JP2020/042317 JP2020042317W WO2021100614A1 WO 2021100614 A1 WO2021100614 A1 WO 2021100614A1 JP 2020042317 W JP2020042317 W JP 2020042317W WO 2021100614 A1 WO2021100614 A1 WO 2021100614A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proline
- glycine
- peptide
- neuropsychological function
- neuropsychological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- the present invention has a neuropsychological function having a preventive and / or ameliorating effect on symptoms and diseases caused by a decrease in neuropsychological function such as Alzheimer-type Dementia (AD) and depression.
- a neuropsychological function improving agent capable of preventing and / or ameliorating a decrease in neuropsychological function by using a soybean peptide and / or collagen peptide that can be safely and easily ingested as an active ingredient.
- Non-Patent Document 1 In recent years, the increase in social security burden has become a major problem due to the rapid increase in the number of elderly people with dementia due to the aging of the world. Moreover, even in healthy seniors, improvement of deterioration of brain function with aging is desired. Therefore, there is a social demand for preventive measures that do not impair brain function, especially cognitive function. In particular, in Japan, it is predicted that one in four people aged 65 and over will have dementia, and it is estimated that more than 60% of them will have Alzheimer's disease (AD) (Non-Patent Document 1).
- AD Alzheimer's disease
- amyloid- ⁇ A ⁇
- tau protein tau protein
- NFT neurofibrillary tangle
- Non-Patent Document 3 Non-steroidal anti-inflammatory drugs
- NSAIDs non-steroidal anti-inflammatory drugs
- Non-Patent Document 5 Alzheimer's disease
- Non-Patent Document 6 It has been reported that hippocampal volume and hippocampal function are reduced in depressed patients.
- the hippocampus is known as a brain region involved in cognitive functions such as memory and learning, but in depressed patients, not only mood disorders but also cognitive functions including memory are impaired.
- the hippocampus negatively regulates the function of the hypothalamic-pituitary-adrenal axis (HPA system), but the HPA system is overactive in depressed patients. It is thought that the hippocampal function is reduced as a factor.
- HPA system hypothalamic-pituitary-adrenal axis
- Non-Patent Document 7 nerve stems and progenitor cells also exist in the stage, and that nerve cells are regenerated by proliferating and differentiating them. It has been reported that nerve cells regenerated in the hippocampal dentate gyrus form a neural network and play an important role such as being involved in memory formation (Non-Patent Document 8). Recently, it has been reported that the neoplasia of nerve cells in the hippocampus decreases sharply as AD progresses, and it has been pointed out that it may be involved in the onset of AD (Non-Patent Document 9).
- Pantoea agglomeras significantly reduces the amount of A ⁇ peptide accumulated in the brain and improves learning function (Patent Document 2), and is a polyphenol found in coffee beans, potatoes, rice bran, etc. It is disclosed that ingestion of chlorogenic acids improves higher brain functions such as cognitive flexibility, executive function, and attention control function (Patent Document 3).
- An object of the present invention is to provide a neuropsychological function improving agent having a preventive and / or ameliorating effect on symptoms and diseases caused by a decrease in neuropsychological function such as Alzheimer's dementia and depression. And.
- the present invention uses a pharmaceutical composition for improving psychological function, a food and drink composition for improving neuropsychological function, and the neuropsychological function improving agent containing the neuropsychological function improving agent. It is an object of the present invention to provide a method for preventing and / or ameliorating symptoms and / or diseases caused by neuropsychological dysfunction.
- the present inventors surprisingly administer soybean peptide and / or collagen peptide. When this is done, it has been found that it has an effect of improving the neuropsychological function, and the present invention has been completed.
- the gist of the present invention is [1] Neuropsychology for the prevention and / or amelioration of symptoms and / or diseases caused by decreased neuropsychological function, which contains a dipeptide containing proline or a tripeptide containing glycine and proline as an active ingredient.
- proline-containing dipeptide or glycine and proline-containing tripeptide Hydroxyproline-Proline, Proline-alanine, Proline-Hydroxyproline, Proline-Proline, Proline-serine, Glycine-Proline-Alanine, Glycine-Proline-Hydroxyproline, Glycine-Proline-Glutamine, Glycine-Proline-Proline, Glycine-proline-leucine,
- the neuropsychological function improving agent according to the above [1] which is one or more selected from the group consisting of glycine-proline-serine and glycine-proline-cysteine.
- a neuropsychological function improving agent for preventing and / or ameliorating symptoms and / or diseases caused by a decrease in neuropsychological function which contains a soybean peptide and / or collagen peptide as an active ingredient.
- Symptoms and / or diseases caused by decreased neuropsychological function are Alzheimer-type dementia, depression, memory disorder due to aging, autism spectrum disorder, bipolar disorder, schizophrenia or chronic fatigue syndrome.
- the neuropsychological function improving agent according to any one of the above [1] to [4].
- the neuropsychological function improving agent according to any one of [3] to [5] above, wherein the soybean peptide is a digested product of thermolysin.
- the soybean peptide contains a peptide consisting of the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), and the collagen peptide is a dipeptide containing proline or a tripeptide containing glycine and proline.
- the neuropsychological function improving agent according to any one of [3] to [6].
- the collagen peptide is Hydroxyproline-Proline, Proline-alanine, Proline-Hydroxyproline, Proline-Proline, Proline-serine, Glycine-Proline-Alanine, Glycine-Proline-Hydroxyproline, Glycine-Proline-Glutamine, Glycine-Proline-Proline, Glycine-proline-leucine,
- the neuropsychological function improving agent according to any one of [3] to [8] above, which is one or more selected from the group consisting of glycine-proline-serine and glycine-proline-cysteine.
- a pharmaceutical composition for improving neuropsychological function which comprises the neuropsychological function improving agent according to any one of [1] to [9] above.
- a food and drink composition for improving neuropsychological function which comprises the neuropsychological function improving agent according to any one of [1] to [9] above.
- a nerve including a step of administering the neuropsychological function improving agent to a patient or a reserve army who needs the neuropsychological function improving agent according to any one of the above [1] to [9]. It relates to a method of preventing and / or ameliorating symptoms and / or diseases caused by a decrease in psychological function.
- the active ingredient soybean peptide and / or collagen peptide is a highly safe material with a long history of use as a food material, and also. Since all of them have the effect of improving the neuropsychological function, the subject who needs the prevention or improvement (treatment) of the disease or condition (symptom) caused by the deterioration of the neuropsychological function should be accompanied by side effects. However, prevention or improvement (treatment) of such diseases or conditions is expected.
- FIG. 1 is a diagram showing core symptoms of dementia and behavioral / psychological symptoms (BPSD).
- FIG. 2 is a diagram showing a method of performing a tail suspension test.
- FIG. 3 is a diagram showing the results of a tail suspension test when synthetic Soy-deprestatin or soybean peptide powder (Soylac) was administered.
- FIG. 4 is a diagram showing the results of a tail suspension test when GABA, theanine, or soybean peptide powder (Soylaz) was administered.
- FIG. 5 is a diagram showing the amount of IL-6 in the brain when GABA, theanine, or soybean peptide powder (Soylaz) was administered.
- FIG. 6 is a diagram showing the results of a tail suspension test when collagen peptide (PCT-A) was administered.
- FIG. 1 is a diagram showing core symptoms of dementia and behavioral / psychological symptoms (BPSD).
- FIG. 2 is a diagram showing a method of performing a tail suspension test.
- FIG. 3 is a diagram showing
- FIG. 7 is a diagram showing the amount of BDNF in the brain when collagen peptide (PCT-A) was administered.
- FIG. 8 is a diagram showing the amount of HGF in the brain when collagen peptide (PCT-A) is administered.
- FIG. 9 is a diagram showing the results of a tail suspension test when soybean peptide powder (Soylac) and collagen peptide (PCT-A) were administered alone or in combination.
- FIG. 10 is a diagram showing the results of a tail suspension test performed in Example 8 when a single dose of a collagen peptide-derived dipeptide was administered.
- FIG. 11 is a diagram showing the results of a tail suspension test performed in Example 8 when a collagen peptide-derived dipeptide was administered for 5 days.
- FIG. 12 is a diagram showing the results of a tail suspension test performed in Example 8 when a single dose of a collagen peptide-derived tripeptide was administered.
- FIG. 13 is a diagram showing the results of the novel object recognition test performed in
- the neuropsychological function improving agent of the present invention can be used for improving the neuropsychological function.
- the "neuropsychological function” refers to general higher brain functions (hereinafter, cognitive function) such as intelligence, memory function, language function, attention, frontal lobe function, and executive function as shown in Table 1.
- cognitive function general higher brain functions
- it refers to a broad concept that includes psychological functions related to the degree of depression, anxiety, and depression.
- the degree of improvement and / or degree of improvement of each of the above functions by ingesting the neuropsychological function improving agent of the present invention can be examined by each test or the like shown in Table 1.
- Improvements in neuropsychological function include improvement of cognitive function and depressive symptoms, suppression of neuropsychological function-related brain atrophy, suppression of brain dysfunction (strengthening functional connection with the hippocampus), and Includes improvement of nerve cell damage due to inflammation.
- Symptoms and / or diseases caused by decreased neuropsychological function include those related to Alzheimer's disease, depression, autism spectrum disorder, bipolar disorder, schizophrenia, or aging. Can be mentioned. Therefore, improvement of neuropsychological function includes treatment of Alzheimer's disease, depression, memory impairment due to aging, autism spectrum disorder, bipolar disorder, schizophrenia, and / or functional aging of the brain. Is done.
- the symptoms of dementia including Alzheimer-type dementia include core symptoms and behavioral / psychological symptoms.
- Core symptoms include memory impairment, disorientation, aphasia, apraxia, agnosia, and executive function dysfunction.
- BPSD has many symptoms, including wandering, excitement, violence, hallucinations, delusions, depression, and filthiness, but the core symptom of cognitive dysfunction is related to the surrounding environment, personality, and psychological state. It is thought that it will appear.
- soybean peptide The neuropsychological function improving agent of the present invention contains soybean peptide as an active ingredient. It is important that the soybean peptide used in the present invention decomposes soybean protein to a specific degree of decomposition.
- the hydrolysis treatment can be carried out on an aqueous dispersion containing soybean protein. It is important that the soybean protein is hydrolyzed by a method that produces a peptide mixture that has the effect of improving the neuropsychological function in the present invention. That is, the hydrolysis of soy protein is preferably enzymatic decomposition by a proteolytic enzyme (also referred to as protease).
- protease for example, a protein in which amino acids are bound in a chain or an endoprotease which is an enzyme that hydrolyzes a peptide bond inside a peptide to form several peptides is preferable. It is also possible to combine one or more types of exo-type proteases, which are enzymes that sequentially cleave amino acids, peptides and the like from the amino-terminal and carboxy-terminals existing at the ends of proteins and peptides. These endo-type proteases and exo-type proteases can be used as long as they are active in the solution environment of the soybean protein material, and for example, proteases derived from microorganisms such as Bacillus can be preferably used.
- Proteases derived from the genus Bacillus include “Samoase (registered trademark) PC10F” (manufactured by Amano Enzyme Co., Ltd.), “Protin SD-AY10” (manufactured by Amano Enzyme Co., Ltd.), and “Protin SD-NY10” (manufactured by Amano Enzyme Co., Ltd.). ), “Protamex” (manufactured by Novozymes Japan Co., Ltd.), etc.
- thermolysin digested product is preferable from the viewpoint of the titer of the neuropsychological function improving effect.
- Thermolysin is a known protease derived from the thermostable bacterium Bacillus thermoproteoliticus (EC 3.4.224.4). Thermolysin can be used as a food additive in Japan.
- a commercially available product such as a food additive grade (for example, the above-mentioned "Samoase (registered trademark) PC10F" (manufactured by Amano Enzyme Co., Ltd.)) can be used.
- thermolysin is not particularly limited as long as it contains soybean beta-conglycinin ( ⁇ -CG) protein.
- ⁇ -CG soybean beta-conglycinin
- soybean itself squeezed soybean oil extracted from soybean (also called meal or defatted soybean), concentrated soybean protein obtained by removing sugars and ash from defatted soybean, and isolated soybean protein obtained by separating only protein from defatted soybean. Examples thereof include Soy Protein Isolate (SPI) and purified ⁇ -CG protein.
- SPI Soy Protein Isolate
- the hydrolysis reaction with thermolysin is carried out under the condition that a peptide having about 10 amino acid residues can be obtained.
- the reaction temperature can be appropriately selected from 30 to 70 ° C., 40 to 70 ° C., 50 to 65 ° C. and the like.
- the reaction time can be appropriately selected from about 30 minutes to 48 hours, about 1 to 10 hours, about 2 to 8 hours, and the like.
- the pH at which the reaction is carried out can be appropriately selected from pH 6.5 to 8.5 and pH 7 to 8.
- the reaction can be carried out under the conditions of a temperature of about 30 to 40 ° C. and a pH of 6.5 to 8.5 (particularly, a pH of about 7.5) for about 2 to 8 hours.
- the thermolysin may be inactivated by heating to a temperature at which the thermolysin is inactivated (for example, heating at a temperature exceeding 80 ° C. for about 5 to 60 minutes).
- the hydrolysis reaction product can be used as it is, and if necessary, the hydrolyzate obtained as described above can be further fractionated by molecular weight by means such as gel filtration and membrane filtration, or adsorption. It can also be obtained as a fractionated product having a molecular weight of 300 to 1500, preferably 500 to 1300, and more preferably 700 to 1100 by using a fractionation means utilizing the adsorption characteristics of a resin or an ion exchange resin.
- the soybean peptide preferably contains a peptide consisting of the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1).
- the soybean peptide having a clear amino acid sequence as described above may be a synthetic product obtained by using a known chemical synthesis method, or may be a derivative as long as the desired effect can be obtained as the soybean peptide. May be good.
- the neuropsychological function improving agent of the present invention contains collagen peptide as an active ingredient.
- the collagen peptide used in the present invention can be produced by a known method from the above-mentioned raw materials containing collagen or gelatin.
- the "collagen peptide” means a decomposition product of a collagen raw material hydrolyzed so as to have an average molecular weight of 100 to 6000.
- the absorbability of the collagen peptide into the body when ingested orally is increased, and the above-mentioned desired neuropsychological function of the present invention is improved in vivo. The effect can be exhibited.
- the collagen raw material remains as it is, or if the average molecular weight of collagen peptide exceeds 6000, the absorption into the body when taken orally decreases, and an efficient neuropsychological function improving effect is exhibited. It is not preferable because it is hindered.
- the collagen peptide used in the present invention is preferably a tripeptide, a dipeptide, or a collagen peptide containing an oligopeptide having about 4 to 12 amino acid residues.
- the tripeptide include Gly-Pro-X (X may be any naturally occurring amino acid residue; the same applies hereinafter), Gly-Leu-X and the like.
- the dipeptide include Gly-Pro, Pro-X, X-Gly and the like.
- a dipeptide containing proline or a tripeptide containing glycine and proline is preferable from the viewpoint of excellent desired effect of improving neuropsychological function.
- the proline-containing dipeptide include hydroxyproline (Hyp) -Pro, Pro-Ala, Pro-Hyp, Pro-Pro, Pro-Ser and the like.
- the glycine- and proline-containing tripeptide include Gly-Pro-Ala, Gly-Pro-Hyp, Gly-Pro-Gln, Gly-Pro-Pro, Gly-Pro-Leu, Gly-Pro-Ser, and Gly-. Pro-Cys and the like can be mentioned.
- oligopeptide examples include those consisting of about 4 to 12 amino acid residues, and among them, n (Gly-Pro-X) n (n represents an integer of 2 to 4) is preferable.
- the tripeptide, dipeptide or oligopeptide may be one obtained by enzymatically digesting collagen or gelatin to contain a dipeptide, or further purified, isolated or synthesized with amino acids.
- the total content of tripeptides, dipeptides and oligopeptides contained in the collagen peptide is preferably 5 to 25% by weight, more preferably 8 to 20% by weight, and most preferably 13 to 20% by weight.
- the collagen peptide having a clear amino acid sequence as described above may be a synthetic product obtained by using a known chemical synthesis method, or may be a derivative as long as the desired effect can be obtained as the collagen peptide. You may.
- the collagen used as a raw material for collagen peptide is not particularly limited, and any of type I to type XIII collagen can be used, and a mixed type collagen which is a mixture of these can also be used.
- collagen is a mixed type collagen obtained from various animals and fish, but the animals (for example, cows, pigs, etc.) and fish (for example, for example) that are the source of this collagen are used.
- the type of collagen, salmon, sardine, tuna, etc.) and the collagen extraction site can be bone, skin, tendon, ukibukuro (fish), etc.
- Extraction and purification of collagen from these components can be carried out by using a commonly known method. Specifically, for example, after crushing collagen-containing tissues such as bone, skin, tendon, and ukibukuro, washing with water, extraction with a dilute salt solution, extraction with an acid or alkaline solution, and enzymes such as pepsin, trypsin, and hyaluronidase are used. It can be obtained by purifying collagen by performing extraction and performing a known purification means such as salting out or dialysis. It can also be obtained as "regenerated collagen" by a commonly known method. It is also possible to use commercially available collagen as a raw material.
- Gelatin is a water-soluble protein obtained by heat-extracting the above-mentioned collagen with water.
- gelatin produced by a commonly known method can be used as a raw material, and a commercially available product can also be used.
- the collagen peptide used in the present invention is produced by reacting collagen or gelatin obtained as described above with an enzyme such as a crude enzyme derived from a natural plant, collagenase, modified collagenase, prolyl endopeptidase and its modifying enzyme. be able to.
- the enzyme is not particularly limited.
- examples of plant raw materials for crude enzymes derived from natural plants include pineapple, kiwi, and ginger.
- the collagenase is not particularly limited, but is derived from bacteria such as Clostridium historyticum, Streptomyces pervulus, etc., and has an amino acid sequence peculiar to collagen [(Gly-).
- a and B represent amino acid residues excluding glycine residues, which may be the same or different from each other, and n represents a positive integer
- a and B represent amino acid residues excluding glycine residues, which may be the same or different from each other, and n represents a positive integer
- the types of amino acid residues other than glycine residues that can be taken by A and B are not particularly limited, and usually, amino acid residues of naturally occurring amino acids (excluding glycine), specifically, alanine.
- the collagen peptide used in the present invention is a free or immobilized carrier such as chitovar according to a commonly known method, for example, a method described in JP-A-7-82299 and JP-A-9-176196.
- the degree of purification can be increased by using a filtration aid such as diatomaceous earth.
- An adsorbent such as activated carbon may be used for decolorization and deodorization.
- Collagen peptide dry powder can be obtained by sterilizing the obtained filtrate and drying it. Examples of the drying method include spray drying, heating under reduced pressure drying, freeze drying, drum drying and the like.
- a fraction having an increased concentration of the low molecular weight peptide can also be obtained.
- collagen or gelatin When collagen or gelatin is decomposed with collagenase by the above method and purified by various methods, the absorption rate and absorption rate of collagen peptide in the digestive tract are increased, the passage of blood-brain barrier is improved, and the stability against heat and protease is improved. It suffices to contain 50% by weight or more of collagen peptide having a molecular weight of 6000 or less from various viewpoints such as improvement of the activity of the peptide itself, increase of the number of moles per unit weight, and the like.
- the average molecular weight of collagen peptide can be measured by a conventional method, and can be measured by, for example, gel filtration chromatography or gel permeation chromatography. The average molecular weight is calculated as a weight average molecular weight.
- the spray drying refers to a method of producing a dry powder by spraying a liquid into a gas and rapidly drying it.
- the heating vacuum drying is a method of promoting drying by depressurizing the inside of a heating device to lower the boiling point, and evaporating and drying with a small amount of energy.
- the freeze-drying refers to a method of first freezing and then lowering the boiling point of the frozen dried product in a vacuum to sublimate the water content of the dried product and dry it. All of these drying methods may be performed using a known drying device.
- the temperature conditions at the time of drying may be set to an appropriate temperature range according to each drying method. For example, the outlet temperature is 50 to 100 ° C. for spray drying, 20 to 100 ° C. for heated vacuum drying, and freeze drying. The temperature may be adjusted to 20 to 60 ° C., but the temperature is not particularly limited.
- collagen peptide a commercially available product can also be used.
- “Nippi Peptide (registered trademark) PCT-A” manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-EX manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-AS manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-AK manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-AM "Nippi Peptide FCP-DP” (manufactured by Nippi Co., Ltd.) and the like
- PCT-A manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-EX manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-AS manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-AK manufactured by Nippi Co., Ltd.
- Nippi Peptide FCP-AM manufactured by
- the commercially available product is a collagen peptide containing a tripeptide, a dipeptide, an oligopeptide, etc.
- a collagen peptide containing a tripeptide, a dipeptide, an oligopeptide, etc.
- "Nippipeptide (registered trademark) PCT-A” contains a relatively large amount of collagen peptide starting with Gly.
- the tripeptide content is 13 to 20% by weight.
- Proline-containing dipeptide or glycine and proline-containing tripeptide contains a proline-containing dipeptide or glycine and proline-containing tripeptide as an active ingredient.
- the proline-containing dipeptide include hydroxyproline (Hyp) -Pro, Pro-Ala, Pro-Hyp, Pro-Pro, Pro-Ser and the like.
- the glycine- and proline-containing tripeptide include Gly-Pro-Ala, Gly-Pro-Hyp, Gly-Pro-Gln, Gly-Pro-Pro, Gly-Pro-Leu, Gly-Pro-Ser, and Gly-. Pro-Cys and the like can be mentioned.
- the proline-containing dipeptide or glycine and proline-containing tripeptide may be obtained by purifying collagen or gelatin after digestion treatment, or may be obtained by amino acid synthesis.
- the first neuropsychological function improving agent of the present invention (hereinafter, the neuropsychological function improving agent of the first aspect) is a dipeptide containing proline or glycine and proline. It contains the contained tripeptide as an active ingredient.
- proline-containing dipeptide or glycine and proline-containing tripeptide examples include Hydroxyproline-Proline (Hyp-Pro), Proline-Alanine (Pro-Ala), Proline-Hydroxyproline (Pro-Hyp), Proline-Proline, Pro-Ser, Glycine-Proline-Alanine (Gly-Pro-Ala), Glycine-Proline-Hydroxyproline (Gly-Pro-Hyp), Glycine-Proline-Glutamine (Gly-Pro-Gln), Glycine-Proline-Proline (Gly-Pro-Pro), Glycine-Proline-Leucine (Gly-Pro-Leu), Glycine-Proline-Serine (Gly-Pro-Ser) and Glycine-Proline-Cysteine (Gly-Pro-Cys) It is preferable that the number is one or more selected from the group consisting of.
- neuropsychological function improving action a symptom and / or disease improving action caused by a decrease in neuropsychological function, specifically, Alzheimer-type dementia, depression, autism spectrum disorder, It is expected to improve bipolar disorder, schizophrenia or chronic fatigue syndrome.
- the second neuropsychological function improving agent of the present invention contains either / or both of the soybean peptide and the collagen peptide as an active ingredient. Is.
- the soybean peptide comprises the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1) as a type of peptide that easily exerts the neuropsychiatric improving function and the synergistic effect.
- the soybean peptide comprises the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1) as a type of peptide that easily exerts the neuropsychiatric improving function and the synergistic effect. Examples thereof include a peptide containing a peptide and the collagen peptide being a dipeptide containing proline or a tripeptide containing glycine and proline.
- the compounding ratio of soybean peptide and collagen peptide is limited as long as a "synergistic effect" in improving neuropsychological function can be obtained.
- it is usually 10 to 90:90 to 10, preferably 20 to 80:80 to 20, more preferably 30 to 70:70 to 30, more preferably 40 to 60:60 to 40, still more preferably 40 to 60. : 60-40, more preferably 45-55: 55-45, most preferably 50:50.
- a mixture containing two components of soybean peptide and collagen peptide is referred to as "soybean-collagen peptide combination”.
- the content of the soybean-collagen peptide combination may be 100% by weight, and when it contains the additional component described later, it is 20% by weight or more. Often, 40% by weight or more is preferable, 60% by weight or more is more preferable, and 80% by weight or more is further preferable. Further, in the case of a solution-like neuropsychological function improving agent in which the soybean-collagen peptide mixture is dispersed and dissolved in a medium such as water, the content of the soybean-collagen peptide mixture is 2% by weight or more. Good.
- the neuropsychological function improving agent of the first aspect or the second aspect may further contain a polysaccharide as an additional component, and if necessary, a bulking agent, a solubilizing agent, a dispersant, a suspension. It may contain components such as agents, emulsifiers, antioxidants, bacterial inhibitors, colorants, flavoring agents, and odorants. All of these additional ingredients are not particularly limited as long as they are used in foods, pharmaceuticals, and pharmaceutical components.
- the total amount of these additional components is 80% by weight or less, preferably 60% by weight or less, more preferably 40% by weight or less, still more preferably 20% by weight, based on 100% by weight of the dry weight of the "neuropsychological function improving agent". It is less than% by weight.
- the neuropsychological function improving agent of the first aspect or the second aspect is blended as an active ingredient and used as a food and drink composition for prevention and / or improvement of symptoms and / or diseases caused by deterioration of neuropsychological function. can do.
- Symptoms and / or diseases caused by decreased neuropsychological function include Alzheimer's dementia, depression, memory impairment due to aging, autism spectrum disorder, bipolar disorder, and schizophrenia.
- non-therapeutic is a concept that does not include medical treatment, that is, treatment of the human body by treatment.
- treatment means returning a disease or symptom that has developed in an application target to a state before the onset.
- prevention means preventing or delaying the onset of a disease in an application target, or reducing the risk of developing a disease or symptom in the application target.
- improved refers to improvement of a disease, symptom or condition; prevention, delay or reversal, prevention or delay of progression of the disease, symptom or condition.
- the food or drink composition containing the neuropsychological function improving agent of the first aspect or the second aspect as an active ingredient is ingested by animals including humans, and a disease or symptom associated with a decrease in neuropsychological function. It can be used as a method for preventing the onset of the disease or for improving or treating a disease or symptom.
- the latest findings indicate that neuronal neoplasia is observed throughout life in the hippocampus of the human brain, but in patients with Alzheimer's disease, neuronal neoplasia rapidly declines as Alzheimer's disease progresses. ing.
- the neuropsychological function improving agent of the first aspect or the second aspect promotes the neoplasia of nerve cells when a dipeptide containing proline or a tripeptide containing proline or a collagen peptide is contained as an active ingredient. This is thought to contribute to the improvement of diseases and / or symptoms associated with a decrease in neuropsychological function.
- Inflammation in the brain refers to a state in which inflammatory cytokines are excessively released in the brain beyond the physiological range and period. It has been pointed out that intracerebral inflammation is also involved in the onset process of Alzheimer's disease, depression, schizophrenia, chronic fatigue syndrome and the like. Microglia, which are glial cells that support nerve cells, are thought to play a central role in intracerebral inflammation because they produce and release inflammatory cytokines in response to infection, tissue damage, neurodegeneration, and the like. Normal microglial function is essential for maintaining homeostasis of the brain, but overactivated microglia release large amounts of inflammatory cytokines and cause intracerebral inflammation.
- Microglia are also activated by the accumulation of A ⁇ and tau protein, which are important for the pathophysiology of Alzheimer's disease.
- the hippocampus which is the memory center, is one of the brain regions with the highest number of microglia in the brain, and is strongly affected by inflammation in the brain.
- the neuropsychological function improving agent of the second aspect improves diseases and / or symptoms associated with a decrease in neuropsychological function by suppressing inflammation in the brain when soybean peptide is contained as an active ingredient. It is thought that it contributes to.
- BDNF Brain-Derived Neurotrophic Factor
- the neuropsychological function improving agent of the second aspect is a disease and / or symptom associated with a decrease in neuropsychological function by increasing the expression of BDNF in the brain when a soybean peptide and a collagen peptide are used in combination. It is thought that it will contribute to the improvement of.
- the food and drink composition includes foods with functional claims, foods for the sick, foods for specified health use, etc., which are based on the concept of prevention, improvement or treatment of various symptoms or diseases caused by deterioration of neuropsychological function. Can be mentioned.
- the food and drink composition may be in the form of liquid, paste, solid, powder, etc., in addition to tablets, liquid foods, feeds (including those for pets), etc., for example, flour products, instant foods, processed agricultural products. , Processed marine products, processed livestock products, milk / dairy products, fats and oils, basic seasonings, complex seasonings / foods, frozen foods, confectionery, beverages, and other commercial foods.
- examples of the wheat flour product include bread crumbs, macaroni, spaghetti, noodles, cake mix, fried chicken flour, bread crumbs and the like.
- examples of the instant foods include instant noodles, cup noodles, retort / cooked foods, canned foods, microwave foods, instant soups / stews, instant miso soups / soups, canned soups, freeze-dried foods, and other instant foods.
- examples of the processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, cereals (processed grain products) and the like.
- Examples of the processed marine products include canned marine products, fish hams and sausages, fish paste products, marine delicacies, and tsukudani.
- examples of the processed livestock products include canned livestock and pastes, livestock ham and sausage.
- milk / dairy products examples include processed milk, milk drinks, yogurts, lactic acid bacteria drinks, cheese, ice creams, formula milk powders, creams, and other dairy products.
- fats and oils examples include butter, margarines, vegetable oils and the like.
- basic seasoning examples include soy sauce, miso, sauces, processed tomato seasonings, mirin, vinegar and the like.
- complex seasonings / foods include cooking mixes, curry ingredients, sauces, dressings, noodle soups, spices, and other complex seasonings.
- frozen food examples include raw material frozen food, semi-cooked frozen food, and cooked frozen food.
- examples of the confectionery include gummies, jellies, caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, and other confectionery.
- the beverages include carbonated beverages, natural fruit juices, fruit juice beverages, soft beverages containing fruit juice, fruit meat beverages, fruit beverages containing fruit grains, vegetable beverages, soy milk, soy milk beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages, and sports. Beverages, nutritional beverages, alcoholic beverages, other favorite beverages and the like can be mentioned. Examples of commercially available foods other than the above include baby food, sprinkle, tea mashed seaweed and the like.
- the neuropsychological function improving agent of the first aspect or the second aspect is used for prevention, improvement and / or treatment for diseases, diseases and symptoms associated with a decrease in neuropsychological function as described above. It can be used in combination with other pharmaceutical ingredients as an active ingredient for human or veterinary drugs, quasi-drugs, etc.
- the drug or quasi-drug containing the neuropsychological function improving agent of the first aspect or the second aspect as an active ingredient may be administered orally or parenterally, but oral administration is preferable.
- Dosage forms for oral administration include tablets, capsules, lozenges, syrups, granules, powders, ointments and the like.
- components such as excipients, pH adjusters, colorants, and flavoring agents that are usually used for formulation can be used. It is also possible to use a functional component having a muscle synthesis promoting action known or found in the future in combination.
- the administration frequency and dose of the neuropsychiatric function improving agent of the first aspect or the second aspect may be appropriately adjusted according to the administration target, age, sex, condition, etc., and the amount of proline capable of exerting the desired effect may be adjusted. It suffices if a dipeptide containing glycine, a tripeptide containing proline, a soybean peptide, a collagen peptide, or the like can be administered to an administration subject.
- the total content of proline-containing dipeptide or glycine, proline-containing tripeptide, soybean peptide, and collagen peptide in the above-mentioned pharmaceutical products, non-pharmaceutical products, etc. is at least 0.001% by mass based on the final product of the preparation.
- the intake or dose of a proline-containing dipeptide or glycine, a proline-containing tripeptide, a soybean peptide, and a collagen peptide varies depending on the species, age, symptoms, etc. of the administration target, but is usually 0.001 to 8000 mg / It is kg body weight / day, preferably 0.01 to 6000 mg / kg body weight / day, most preferably 0.01 to 4000 mg / kg body weight / day, and may be administered once to three times a day.
- the intake or dose for humans is 0.001-1500 mg / kg bw / day, preferably 0.01-1000 mg / kg bw / day, most preferably 0.01-500 mg / kg bw / day.
- proline-containing dipeptide or glycine, proline-containing tripeptide, soybean peptide, and collagen peptide for administration to humans is "HED (Human Equivalent Dose) exchange from animals based on body surface area” ( For example, it can be calculated from the conversion formula according to (see Reference 1 below).
- HED [Dose to animals (mg / kg body weight)] x ⁇ [Animal body weight (kg)] ⁇ [Human body weight (kg)] ⁇ 0.33 Human weight: 60 kg Rat weight: 200g
- Reference 1 Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Health Volunteer STEP 2: HUMAN EQUIVALENT Dose CALCURATION, July 2005, Pharmacology and Toxicology, p. 6-7 / U.S. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER)
- soybean peptide was prepared as follows. That is, 0.5 kg of soybean-separated protein (SPI, Spro 661, DuPont Co., Ltd.) was suspended and dissolved in 4.5 kg of water. The mixture is heated to 60 ° C. with stirring, a 10M sodium hydroxide solution is added so that the pH becomes 7.0 ( ⁇ 0.1), and then Samoase (registered trademark) PC10F (manufactured by Amano Enzyme Co., Ltd.) is added. 5 g was added, and the mixture was reacted at 60 ° C. for 5 hours with stirring.
- SPI soybean-separated protein
- the content of the decapeptide LSSTQAQQSY (SEQ ID NO: 1; Soy-deprestatin) contained in the soybean peptide powder (Soylax) was measured under the following measurement conditions.
- ⁇ LC-MS / MS analysis conditions As the HPLC apparatus and the mass spectrometer, Alliance 2695 HPLC system (Waters) and 3200 Q Trap (AB SIX Co., Ltd.) were used, respectively.
- the column used was Capcell PAK C18 UG80 (2.0 ⁇ 150 mm, 5 ⁇ m) (manufactured by Osaka Soda Co., Ltd.).
- solution A 0.1 v / v% formic acid water
- solution B 0.1 v / v% formic acid-containing acetonitrile
- the gradient condition was set to 0 to 15 minutes (0 to 70 v / v% B) ⁇ 15 Minutes to 20 minutes (70v / v% B to 70v / v% B) ⁇ 20 minutes to 25 minutes (70v / v% B to 100v / v% B) ⁇ 25 minutes to 35 minutes (100v / v% B) ⁇ 35 minutes to 35.01 minutes (100 to 0v / v% B) v / v% B) ⁇ 10 minutes to 10.01 minutes (100v / v% B to 10v / v% B) ⁇ 10.01 minutes to 11 Minutes (10 v / v% B).
- the flow velocity was 0.2 mL / min.
- the MRM method multiple reaction monitoring
- the ionization method is ESI (positive mode)
- the precursor ion is detected at 112.7 (m / z) and the product ion: 101.1 (m / z).
- the standard product of the decapeptide LSSTQAQQSY was synthesized by the Fmoc method and purified by reverse phase HPLC.
- a calibration curve was prepared by dissolving in peptone water (0.1% aqueous solution of Bacto peptone).
- the produced soybean peptide was dissolved in peptone water at a concentration of 10 mg / ml, and 10 ⁇ L was injected for analysis.
- the concentration of the decapeptide LSSTQAQQSY in the produced soybean peptide powder was 0.97 mg / g.
- Example 2 Comparison of effects of soybean peptide powder (Soylax) and synthetic peptide (Soy-peptide) 8-week-old Slc: ddY mouse (Nippon SLC Co., Ltd.) chemically synthesized decapeptide LSSTQAQQSY (SEQ ID NO:) 1; Soy-peptide powder (Soylax) adjusted so that the Soy-peptide content is 0.1 mg / kg BW or the Soy-peptide content is the same amount as described above, 0.1 mg / kg BW, is administered to the stomach sonde, respectively. did. A solvent (water) was administered to the Control group as a sonde.
- the mouse was hung by fixing the tail of the mouse to a horizontally placed rod with tape, and the observation of the state of the mouse was started immediately after the suspension, and during 6 minutes.
- the immobility time was measured, and the ratio (%) of the immobility time to the total measurement time was calculated by the formula of immobility time (seconds) / 360 (seconds) ⁇ 100.
- administration of a substance having an antidepressant effect reduces the time of this immobility. Therefore, when a decrease in immobility time is observed, it can be evaluated as having an antidepressant-like effect.
- Akinesia is considered to be a state of despair, and a decrease in akinesia time is also an indicator of improvement of the state of despair, that is, improvement of motivation.
- the results are shown in Fig. 3.
- the ratio of immobility time was about 32.5% for Control, while about 22.6% (no significant difference) for chemically synthesized decapeptide LSSTQAQQSY (SEQ ID NO: 1; Soy-peptide), soybean.
- the peptide powder (Soylaz) was about 10.1% (P ⁇ 0.05), and it was confirmed that the soybean peptide powder had an antidepressant effect higher than that of Soy-deptrestin.
- Example 3 Comparison of antidepressant effect of soybean peptide with other antidepressant functional ingredients
- GABA was 1 mg / kgBW
- theanine was 1 mg / kgBW
- soybean peptide powder soybean peptide powder (soybean peptide powder). Soylax) is administered in a gastric sonde so as to have a dose of 100 mg / kgBW (equivalent to Soy-peptide (0.1 mg / kgBW)) or 500 mg / kgBW (equivalent to Soy-peptide (0.5 mg / kgBW)). did.
- LPS lipopolysaccharide
- Example 4 Anti-inflammatory effect of soybean peptide
- the amount of interleukin-6 (IL-6) in the brain of mice was measured. 40 minutes after the final sample administration in Example 3, mouse brains were harvested and cryopreserved at ⁇ 80 ° C. Thaw the cryopreserved brain, homogenize in 1.5 ml of RIPA buffer (containing protease inhibitor cocktail), and centrifuge (25,000 xg, 10 min, 4 ° C.) to measure the amount of IL-6 in the supernatant. It was measured using an IL-6 ELISA kit (R & D Systems). In addition, the protein concentration in the supernatant was measured using the BCA protein assay kit.
- RIPA buffer containing protease inhibitor cocktail
- Example 6 Effect of administration of collagen peptide on the amount of BDNF and HGF in the brain
- the brain was collected 40 minutes after the administration of collagen peptide and cryopreserved at ⁇ 80 ° C. Thaw the cryopreserved brain, homogenize in 1.5 ml of RIPA buffer (containing protease inhibitor cocktail), and centrifuge (25,000 xg, 10 min, 4 ° C.) to determine the amount of BDNF in the supernatant. It was measured using an ELISA kit (R & D Systems).
- the amount of HGF at the time of administration of collagen peptide was measured using Mouse / Rat HGF Quantikine ELISA Kit.
- the protein concentration in the supernatant was measured using a BCA protein assay kit (manufactured by Thermo).
- Total BDNF and HGF values were calculated as concentrations per protein amount.
- the measurement result of the total BDNF amount is shown in FIG. 7, and the measurement result of the HGF amount is shown in FIG. From the results shown in FIG. 7, a significant increase in the amount of Total BDNF was observed in the collagen peptide (100 and 500 mg / kg BW) -administered group as compared with the Control group.
- BDNF brain-derived neurotrophic factor
- HGF brain-derived neurotrophic factor
- NG2 glia central nervous system progenitor cells
- HGF stem cell growth factor
- Example 4 show that the soybean peptide has an anti-cerebral inflammatory effect
- Example 6 show that the inclusion of collagen peptide has the effect of increasing the amount of BDNF and HGF in the brain.
- the neuropsychological function improving agent of the present invention containing the components of the present invention is used for neurological diseases such as Alzheimer's disease, autism spectrum disorder, bipolar disorder, schizophrenia or chronic fatigue syndrome, which are central nervous system diseases, in particular. It is considered to have an improving effect on Alzheimer's dementia.
- Example 8 Effect of dipeptide and tripeptide derived from collagen peptide
- OP Hydroxyproline-proline
- PA proline-alanine
- PO proline-hydroxyproline
- PP proline-proline
- proline-serine PS
- GPO Glycine
- 6-week-old Slc ddY mice were administered 1 mg / kg BW of each peptide dissolved in water in a gastric sonde, and 45 minutes after the administration, immobility during the 6-minute test time in a tail suspension test. The time (seconds) was measured and the immobility time (%) with respect to the test time was calculated. Then, as administration for 5 days, 6-week-old Slc: ddy mice were administered with gastric sonde at 1 mg / kg BW / day of each peptide dissolved in water for 5 days.
- the akinesia time (seconds) during the 6-minute test period was measured in a tail suspension test, and the akinesia time (%) with respect to the test time was calculated.
- the one to which only water was administered was used as a control.
- the result of a single administration of the dipeptide is shown in FIG. 10
- the result of the 5-day administration of the dipeptide is shown in FIG. 11
- the result of the single administration of the tripeptide is shown in FIG.
- the immobility time in the tail suspension test was reduced by a single dose as compared with the control, and in particular, OP, PL, PO, PP, PS. , GPA, GPO, GPW, GPP, GPL, GPS, GPC had significant differences compared to controls.
- the 5-day administration of PA had the effect of reducing the akinesia time as compared with the control. From the above, it was shown that the dipeptides and tripeptides used had antidepressant effects.
- Example 9 Evaluation test for suppression of cognitive decline using aging-accelerated mice Originally, rodents such as mice approach when they recognize an object as novel, and take exploratory actions such as confirming the shape and smelling. .. At this time, there is a property that the search action is not taken for the object that has already been memorized, or the search is performed only for a shorter time than the novel object. Therefore, a novel object recognition test is known as a method for evaluating the memory retention effect and cognitive function of mice by utilizing this property of mice, and the actions of soybean peptide and collagen peptide were investigated.
- mice 20-week-old aging-accelerated mice (SAMP8) were mixed with a control feed group (normal feed "AIN-93M", 8 animals) and a test feed group (normal feed containing 2.5% Soylax and 2.5% collagen peptide). , 8 animals), 6 g of feed was given for one day, and the animals were bred for 20 weeks with free intake with drinking water.
- AIN-93M normal feed "AIN-93M”
- test feed group normal feed containing 2.5% Soylax and 2.5% collagen peptide
- the novel object recognition test was conducted as follows. That is, the mice were placed in a plastic cage having a length of 38 cm, a width of 55 cm, and a height of 27 cm, and were acclimatized to the environment for 10 minutes (acclimation trial). The next day, the same object (A1 and A2: both triangular prisms) was placed in the cage, and the mouse was allowed to freely search for the object for 5 minutes, and the behavior was recorded in a video (training trial). One hour after removing the mouse from the gauge, one of the objects was replaced with a new object (B: cylinder), the trained mouse was returned to the cage, and a 5-minute exploratory behavior was recorded on video (acquisition attempt).
- A1 and A2 both triangular prisms
- the number of contacts in which the mouse pierced an object A (known object) or B (a novel object) with the tip of the nose in the acquisition trial was measured using a counter as the number of searches. From the measured values, the ratio of the number of searches for novel objects to the total number of searches for objects was calculated and used as the novel object recognition rate.
- This test was performed before ingestion of the control feed or test feed, and the two groups were grouped so that the recognition rate of novel objects was average, and the control feed or test feed was ingested for 4 weeks, 8 weeks, 12 weeks, and 16 weeks. The test was performed 20 weeks later.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021558343A JP7764992B2 (ja) | 2019-11-19 | 2020-11-12 | 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-208777 | 2019-11-19 | ||
| JP2019208777 | 2019-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021100614A1 true WO2021100614A1 (ja) | 2021-05-27 |
Family
ID=75981290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2020/042317 Ceased WO2021100614A1 (ja) | 2019-11-19 | 2020-11-12 | 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7764992B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021100614A1 (cg-RX-API-DMAC7.html) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022168413A1 (ja) * | 2021-02-04 | 2022-08-11 | ユーハ味覚糖株式会社 | デプレスタチン含有組成物の製造方法 |
| WO2023114846A1 (en) * | 2021-12-15 | 2023-06-22 | Digestome Therapeutics, Inc. | Uses of therapeutic peptides |
| WO2024117210A1 (ja) * | 2022-12-01 | 2024-06-06 | 国立大学法人京都大学 | ペプチド含有組成物 |
| WO2024259556A1 (en) * | 2023-06-19 | 2024-12-26 | Viage Therapeutics, Inc. | Uses of therapeutic peptides |
| WO2025219351A1 (en) * | 2024-04-15 | 2025-10-23 | Rousselot Bv | Collagen peptide composition and use thereof in ameliorating neurological conditions and fibrosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007537699A (ja) * | 2003-06-30 | 2007-12-27 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
| JP2010104364A (ja) * | 2009-09-18 | 2010-05-13 | Uha Mikakuto Co Ltd | 神経新生促進剤を含有する飲食品 |
| JP2010529128A (ja) * | 2007-06-08 | 2010-08-26 | マサチューセッツ インスティテュート オブ テクノロジー | レット症候群および他の障害の処置 |
| JP2011111440A (ja) * | 2009-11-30 | 2011-06-09 | Uha Mikakuto Co Ltd | 神経細胞分化促進剤 |
-
2020
- 2020-11-12 WO PCT/JP2020/042317 patent/WO2021100614A1/ja not_active Ceased
- 2020-11-12 JP JP2021558343A patent/JP7764992B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007537699A (ja) * | 2003-06-30 | 2007-12-27 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
| JP2010529128A (ja) * | 2007-06-08 | 2010-08-26 | マサチューセッツ インスティテュート オブ テクノロジー | レット症候群および他の障害の処置 |
| JP2010104364A (ja) * | 2009-09-18 | 2010-05-13 | Uha Mikakuto Co Ltd | 神経新生促進剤を含有する飲食品 |
| JP2011111440A (ja) * | 2009-11-30 | 2011-06-09 | Uha Mikakuto Co Ltd | 神経細胞分化促進剤 |
Non-Patent Citations (6)
| Title |
|---|
| KASHIMA,YASUHIRO ET AL: "About assessment of the psychological and physiological impact of chewable tablets containing soy-derived peptides on users Randomized, placebo-controlled crossovercomparative test-", JPN. PHARMACOL. THER., vol. 47, no. 9, 20 September 2019 (2019-09-20), pages 1425 - 1431 * |
| KATAYAMA, S. ET AL.: "Oral Administration of Soy Peptides Suppresses Cognitive Decline by Induction of Neurotrophic Factors in SAMP8 Mice", J. AGRIC. FOOD CHEM., vol. 62, no. 16, 23 April 2014 (2014-04-23), pages 3563 - 3569, XP055825528 * |
| MIZUSHIGE, T.: "Ginger-Degraded Collagen Hydrolysate Exhibits Antidepressant Activity in Mice", J. NUTR. SCI. VITAMINOL., vol. 65, no. 3, 30 June 2019 (2019-06-30), pages 251 - 257, XP055825525 * |
| NAGAI, AKITOSHI ET AL: "Antidepressant action of collagen peptide, ProHyp", LECTURE ABSTRACTS OF THE 71ST ANNUAL MEETING OF JAPAN SOCIETY OF NUTRITION AND FOOD SCIENCE, 2017, pages 207 * |
| PEI, X. ET AL.: "Marine collagen peptide isolated from Chum Salmon (Oncorhynchus keta) skin facilitates learning and memory in aged C57BL/6J mice", FOOD CHEMISTRY, vol. 118, 2010, pages 333 - 340, XP026497676, DOI: 10.1016/j.foodchem.2009.04.120 * |
| YUKIHA MORI, SAHO ASAKURA, AKANE YAMAMOTO, SAORI ODAGIRI, DAISUKE YAMADA, MASAYUKI SEKIGUCHI, KEIJI WADA, MASARU SATO, ATSUSHI KUR: "Characterization of soy-deprestatin, a novel orally-active decapeptide that exerts antidepressant-like effects via gut–brain communication", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, & EXPERIMENTAL BIOLOGY MEETING; SAN DIEGO, CA, USA; APRIL 21 -25, 2018, vol. 32, no. 2, 27 September 2017 (2017-09-27), & EXPERIMENTAL BIOLOGY MEETING; SAN DIEGO, CA, USA; APRIL 21 -25, 2018, pages 568 - 575, XP055424793, ISSN: 0892-6638, DOI: 10.1096/fj.201700333RR * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022168413A1 (ja) * | 2021-02-04 | 2022-08-11 | ユーハ味覚糖株式会社 | デプレスタチン含有組成物の製造方法 |
| WO2023114846A1 (en) * | 2021-12-15 | 2023-06-22 | Digestome Therapeutics, Inc. | Uses of therapeutic peptides |
| WO2024117210A1 (ja) * | 2022-12-01 | 2024-06-06 | 国立大学法人京都大学 | ペプチド含有組成物 |
| WO2024259556A1 (en) * | 2023-06-19 | 2024-12-26 | Viage Therapeutics, Inc. | Uses of therapeutic peptides |
| WO2025219351A1 (en) * | 2024-04-15 | 2025-10-23 | Rousselot Bv | Collagen peptide composition and use thereof in ameliorating neurological conditions and fibrosis |
| WO2025219352A1 (en) * | 2024-04-15 | 2025-10-23 | Rousselot Bv | Collagen peptide composition and use thereof in ameliorating neurological conditions and fibrosis |
| BE1032502B1 (nl) * | 2024-04-15 | 2026-04-21 | Rousselot Bv | Collageenpeptidesamenstelling en gebruik daarvan bij het verlichten van neurologische aandoeningen en het verbeteren van hersengerelateerde functies |
| AU2025257522B2 (en) * | 2024-04-15 | 2026-05-14 | Rousselot Bv | Collagen peptide composition and use thereof in ameliorating neurological conditions and fibrosis |
| BE1032501B1 (nl) * | 2024-04-15 | 2026-07-06 | Rousselot Bv | Collageenpeptidesamenstelling en gebruik daarvan bij het verlichten van neurologische aandoeningen en fibrose |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7764992B2 (ja) | 2025-11-06 |
| JPWO2021100614A1 (cg-RX-API-DMAC7.html) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7764992B2 (ja) | 大豆ペプチド及び/又はコラーゲンペプチド含有神経心理学的機能改善剤 | |
| JP5832049B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
| JP6189994B2 (ja) | ジペプチジルペプチダーゼ−iv阻害用飲食品組成物 | |
| JP6344796B2 (ja) | 高齢者用アルツハイマー型認知症改善剤 | |
| JP5976004B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
| WO2003044044A1 (en) | Novel peptide having angiotensin convertase inhibitory effect | |
| JP7358239B2 (ja) | エネルギー消費促進用組成物 | |
| JP2007523940A (ja) | 抗高血圧ペプチド | |
| JP5972235B2 (ja) | 血中トリグリセライド低下剤 | |
| JP2015084694A (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
| JP7856910B2 (ja) | 神経心理学的機能改善剤 | |
| EP4317173A1 (en) | Peptide and composition containing peptide as active ingredient | |
| JP7787424B2 (ja) | デプレスタチン含有組成物の製造方法 | |
| JP5877560B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
| JP2000312567A (ja) | 生理活性健康食品 | |
| JP6083085B2 (ja) | アンジオテンシン変換酵素阻害剤およびその用途 | |
| JP5382633B2 (ja) | 脳血管性認知症の予防または治療薬 | |
| JP7088777B2 (ja) | Glut1発現亢進剤 | |
| JP6589011B2 (ja) | 脳機能障害改善用経口組成物 | |
| JP2020152648A (ja) | 交感神経活性化用組成物 | |
| JP2005239686A (ja) | 脂肪燃焼促進組成物及び該組成物を含有する食品又は医薬品 | |
| JP2005255670A (ja) | ローヤルゼリー由来の降圧ペプチド | |
| JP2005053812A (ja) | アンジオテンシンi変換酵素阻害剤及びその製造方法、並びに機能性食品 | |
| JP2024033770A (ja) | 脳機能低下の予防、治療、又は軽減用組成物、及び、アミロイドβ凝集体の蓄積抑制のための組成物 | |
| JP2025137253A (ja) | ラクトフェリン加水分解物の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20889208 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2021558343 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20889208 Country of ref document: EP Kind code of ref document: A1 |